Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis

Yue Wu1,2†, Ting Wang1,2†, Lin Xia3 and Mei Zhang1,2*

In the original article, the author would like to make the below changes in bold.

**Western blotting.**
RIPA buffer (Sigma, USA) was used to isolate protein, and there proteins were then separated by 10% SDS-PAGE, transferred to PVDF membranes (Millipore, MA, USA).

**Results.**

The levels of lncRNA WDFY3AS2 in OC cells with different levels of cisplatin sensitivity.

SDC4 expression in A2780-DDP cells was inhibited by the miR-139-5p mimic, while SDC4 expression was increased in the miR-139-5p inhibitor group (Fig. 5C, D, P < 0.001). The correlation analysis demonstrated that SDC4 expression was negatively correlated with miR-139-5p (r = -0.6851, P < 0.01 Fig. 5E). These findings indicated that SDC4 was targeted by miR-139-5p negatively.

Furthermore, co-transfection of the miR-139-5p inhibitor could rescue the SDC4 expression reduced by si-WDFY3-AS2 in A2780-DDP cells (Fig. 5F, G, P < 0.001).

The weights and volumes of tumors in animals that had been administered the miR-139-5p inhibitor or SDC4 were notably increased relative to the si-WDFY3-AS2 mice (all P < 0.001, Fig. 7D-F).

We found that overexpression of the WDFY3-AS2 increased cell viability, migration, and invasion, inhibited apoptosis, as well as OC CSC traits induction, as shown by induced tumor sphere formation, CD44-,CD166-positive cell numbers, and the expression levels of CSC markers both in vitro and in vivo.

Accepted: 1 August 2023
Published online: 23 August 2023

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Correspondence:
Mei Zhang
zhangmei@ahmu.edu.cn

1Department of Integrated Chinese and Western Medicine Oncology,
The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei 230022, Anhui, China
2The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui Medical University, 81 Meishan Road, Hefei 230032, China
3Graduate School of Anhui, University of Traditional Chinese Medicine, Hefei 230012, Anhui, China